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Abstract. Chronic kidney disease (CKD) in Indonesia often occurs in elderly (geriatric) patients
with various complications that cause polypharmacy which can increase the risk of drug-drug
interactions (DDIs). This study aimed to determine the incidence of DDIs and actual adverse
events in geriatric patients with CKD. This was a descriptive study where the samples were
collected retrospectively from medical record of the patients admitted in one tertiary care hospital
in Jakarta. Potential drug interaction was screened electronically using a drug interaction
checker (drugs.com) and manually by Drug Interaction Fact 2014. A total of 699 potential DDIs
were detected from 135 patients from one-year study period. The incidence of DDIs was 92.60%
with 5.01% actual adverse event detected due to DDIs. Pharmacodynamic interactions
accounted for 46.64% with the most significant level at a moderate level (59.37%). In conclusion,
The prevalence of DDIs in geriatric patients with CKD was found high and major level of
significance adverse event hyperkalemia was found caused by the DDIs.
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1 Introduction
1. The elderly population is rising rapidly. Since 2015
the elderly population (60 years and older) in Asian
including Indonesia increased by more than 7% [1].
Aging may alter physiological function increase the
risk of communicable or non-communicable diseases.
Four in every 100 elderly people are experiencing pain
[2]. Ministry of the health of Indonesia reported that
most of the geriatric inpatients (36.44%) stay in a
hospital for a period of three days or less where
35.05% may have longer stay (4-7 days). Additionally,
the ministry of health of Indonesia reported that 14.5%
of elderly patients will remain in a hospital for
treatment for a period longer than three weeks [1].
Among these last group of patients, complications due
to Chronic Kidney disease (CKD) was one of the top
ten cause of admission in medical elderly patients [2].
Chronic Kidney Disease (CKD) has a large global
prevalence with steady estimated global CKD
prevalence of more than 10 to 13% with mostly at
stage 3 [3,4]. A study in Indonesia reported the
incidences rate per million population of End Stage
Renal Diseases (ESRD) who underwent hemodialysis
and on hemodialysis from 2002 through 2006 were
higher than 10 [5,6].
The management therapy of CKD often involves
multiple medications to get treatment goals purposed at
slowing progression of CKD, treating complications
and relieving symptoms. The management of CKD and
co-morbidities makes polypharmacy a highly prevalent
occasion in this population [7]. This makes drug-drug
interactions (DDIs) often occur in patients. A study
found polypharmacy in 74.9% of geriatric patients and
within 91% patients had at least one potential DDIs [8].
DDIs is common in elderly. A study conducted in
Yogyakarta-Indonesia showed out of the 100 cases of
elderly patients, 65% cases had experienced potential
DDIs range from 1 to 17 and of total 204 DDIs
incidences, 25% were significance level 1 and 39% of
significance level 2 [9]. A study reported a total of 365
DDIs were identified from 87 patients. Based on this
study severity classification 244 (66.80%) moderate
interactions were most common. Among the
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interaction 116 (31.70%) were of delayed onset and 74
(20.27%) were of rapid onset [10].
The DDIs that occur in patients has a possibility to
generate adverse events (ADEs) in patients. A study
showed 295 ADEs found in older adults among 20,628
visits of patients [11]. Another study reported older
patients had the highest age-specific ADEs rate
between 2005 and 2007 [12].
In regard to CKD, a study reported lisinopril and
furosemide were the most frequent interaction
prescribed drugs that were nephrotoxic affect serum
potassium levels and implicated for DDIs [13]. The
global economic impact of CKD is considerable to it
requires a global effort to raise awareness of CKD, to
incorporate prevention of CKD program in the public
health agenda and to implement programs for early
screening and detection of CKD [14]. Meanwhile,
DDIs in geriatric with CKD in Indonesia especially in
Jakarta is not well-documented. Therefore, the purpose
of this study was conducted to determine the incidence
of DDIs and actual adverse events in geriatric patients
with CKD in one hospital in Jakarta.
2 Methodology
This was a descriptive which conducted in Islamic
Hospital Jakarta Cempaka Putih. Data collection was
taken from geriatric patients’ hospitalization with CKD
in 2017 which conducted retrospectively. The eligible
inpatients were selected with inclusion criteria: age 60
or older, main diagnosed with CKD, and prescribed at
least 2 drugs. Patients who were pregnant and died
were excluded from this study. Drug profile containing
herbal product or topical only including: creams,
ointments, gels, patches, drops, sprays and inhalers
were also excluded.
Potential drug interaction was screened electronically
using a drug interaction checker which was accessed
drugs.com and manually by Drug Interaction Fact 2014.
Potential drug-drug interactions (DDIs) were grouped
according to the mechanism, onset and the level of
significance of the interaction. Meanwhile, the actual
adverse event were checked retrospectively based on
medical history of the patients.
This study was approved by the Universitas
Muhammadiyah Prof DR. HAMKA Ethics Committee
(01/18.09/034).
3 Result and Discussion
During 2017 there were 426 hospitalized patients with
CKD. Two hundred and ninety-one of the patients
were excluded because of died during the treatment
(198 patients) and incomplete medical record such as
laboratory information in their medical record (93
patients). So the final samples in this study were 135
patients.
3.1 Characteristics
Socio-demographic characteristics, the patients in this
study were mostly male with classification age 60-75
year. In regard to clinical characteristics, patients in
this study mostly had a length of stay 3-5 days with
number recipes 3-5 and number of drugs 5-8 items.
These characteristics can be seen in Table 1.
Table 1. Patients’ socio-demographic and clinical characteristics
Characteristic n %
Gender
Male 72 53.3
Female 63 46.7
Age (year)
60-75 74 54.8
76-90 61 45.2
Length of stay (day)
3-5 101 74.8
6-8 34 25.2
Number of recipes
3-5 101 74.8
6-8 34 25.2
Number of drugs
5- 8
9-12
95
40
70.4
29.6
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The overview of drug interactions is shown in Table 2.
The percentage of potential DDIs showed that almost all
geriatric patients got regimen of drugs.
Table 2. Overview Potential DDIs
Characteristic DDIs n %
Patients who had the potential DDIs 125 92.6
Patients who did not have the potential DDIs 10 7.4
Total 135 100
Mechanism of DDIs
Pharmacokinetic 317 45.35
Pharmacodynamic 326 46.64
Unknown 56 8.01
Total 699 100
Onset of DDIs :
Rapid 31 4.43
Delayed 184 26.32
Unknown 484 69.25
Total 699 100
Level of Significance :
Major 74 10.59
Moderate 415 59.37
Minor 210 30.04
Total 699 100
Based on its mechanism, the DDIs are divided into
pharmacokinetic interactions, pharmacodynamic
interactions. These type of mechanisms can be seen in
all patients who had potential drug interactions. Among
135 patients, 699 potential DDIs were identified.
Pharmacodynamic and pharmacokinetic DDIs were
most common constituting 46.64% and 45.35%,
respectively. Meanwhile, the other 8.01% were
unknown.
The most common pharmacodynamic interactions are
interactions between Amlodipine and calcium
carbonate (CaCO3) as many as 45 (13.50%)
occurrences of interactions. This similar to another
study which showed calcium carbonate and amlodipine
were most common potential DDIs in CKD with 114
times frequency [15]. The combination use of the two
drugs can make effects of amlodipine declined. The
recommendation to this case may need a dose
adjustment of blood pressure monitoring [16].
The most common pharmacokinetic interactions were
between Ranitidine and CaCO3 interactions as many as
35 (11.04%) occurrences of interactions. Oral antacids
which consist of for instance calcium salts may reduce
the plasma concentration of oral H2 blockers. The
recommendation in this case is H2 blockers should be
given one to two hours before one of these preparations
[16]. Reduction gastric absorption and bioavailability
ranitidine occur because of the neutralizing effect of
antacid (calcium salt) was suspected mechanism [17]
In this study, the most common rapid onset of drug
interactions was between aspirin and nitroglycerin with
15 (48.39%) interactions. The administration of aspirin
reported can increase the antihypertensive effect of
nitroglycerin. This mechanism is unknown but might
be related to the prostaglandin system. Though this is
minor interaction, the management monitoring blood
pressure during co-administration may be considered
[16].
The most common delayed-onset drug interactions
were between aspirin and furosemide as many as 23
(12.5%) interaction events. This interaction occurs as a
result of prostaglandin inhibition resulting from aspirin
use, which disrupts the effects of furosemide [16].
In this study, the most major interactions were between
omeprazole and clopidogrel, which occurred in 14
(18.92%) interactions. Co-administration with proton
pump inhibitors (PPIs) may reduce the cardioprotective
effect of clopidogrel [16]. Clopidogrel needs
bioactivation by cytochrome P450 2C19 in the liver in
order to exert its inhibitory effect on platelet
aggregation, while competitive inhibition of this
isoenzyme by PPIs impair activation of clopidogrel
[18,19].
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Among the 699 potential DDIs, 21 times the actual
adverse event was found which can be seen in Table 3.
There were three kinds of actual adverse event that found
in this study, i.e hyperkalemia, hypomagnesemia and
increased hypokalaemia.
Table 3. Actual Adverse event from DDIs
No Actual adverse event Name of drugs n %
1. Hyperkalaemia Spironolactone - KCL 2 9.52
Spironolactone-
Candesartan
2 9.52
Spironolactone-
Telmisartan
3 14.29
Spironolactone-Captopril 1 4.76
Captopril – KCL 1 4.76
2. Hypomagnesemia Furosemide-Omeprazole 6 28.57
Furosemide –
Lansoprazole
3 14.29
3. Hypomagnesemia
and/or Hypocalcemia
Furosemide – Digoxin 3 14.29
Total 21 100
Hypomagnesemia caused by furosemide-omeprazole
were the most common actual adverse event (28.57%),
while the other proton pump inhibitor (PPIs)
lansoprazole was also causing the effect in concomitant
with furosemide (14.29%). This was a moderate level
of significance DDI. Patients found to experienced
hypomagnesemia with plasma magnesium from 1.5 to
1.7 after 1 to 5 days co-administration of the drugs.
Hypomagnesemia may occur during long-term
combination PPIs and diuretic. Hypomagnesemia can
occur during long-term PPI use is unknown, although
changes in magnesium intestinal absorption may be
seen. The recommendation in this case is monitoring of
serum magnesium levels periodically before and after
starting therapy [16,20]. A study conducted among
hemodialysis patients to investigate the relationship
between PPIs use and hypomagnesemia found that
furosemide use is a risk factor for hypomagnesemia
[21].
The major significance level of DDIs which were
between spironolactone and KCL, candesartan,
telmisartan, captopril as well as between captopril and
KCL found to cause actual hyperkalemia with range
plasma potassium level from 5.2 to 6 mEq/L. The
patients experienced hyperkalema after 1 to 6 days
after the combination drugs administration. Potassium
sparing agent and potassium itself in KCL will increase
the plasma potassium level. The use of angiotensin
converting enzyme inhibitor (ACEIs) such as captopril
or angiotensin II receptor blockers (ARBs) such as
losartan, candesartan, telmisartan caused in decreased
aldosterone, which can cause potassium retention. As a
results, hyperkalemia often happened in pasien who
using the concomitant of the drugs [16].
Meanwhile there were 3 case of actual drug event
which found in moderate DDIs between furosemide
and digoxin. Three patients found to have hypokalemia
and/or hypomagnesemia with plasma potassium level
3.2-3.4 mEq/L and/or plasma magnesium level around
1.5 -1.7 mEq/L after 1 to 3 days after got the
combination drugs. The mechanism hypomagmesemia
induced by proton pump inhibitors (PPIs) is still
unknown, although it has been reported that there is a
change in intestinal absorption of magnesium. There
has been reports that hypomagnesemia associated with
long-term use of PPIs [20,22]. Hypomagnesemia can
also cause disturbed secretion of parathyroid hormone
which may cause hypocalcemia [16].
Conclusion
The prevalence of DDIs in geriatric patients with CKD
was found high and major level of significance adverse
event hyperkalemia was found caused by the DDIs.
The most common DDIs with major significance level
and frequently generate the actual adverse event in
geriatric patients need to be watched out by clinicians.
The critical role of the clinical pharmacy lies in
detection, prevention, and management of DDIs and
actual adverse events so that the goal of improvement
of therapeutic outcomes can be achieved.
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